Skip to main content
NINDSNIMHNICHDNIDCDNEINIDCRNIANIAAANIDANHGRI NCCIHNIDDKNIEHSCCB

Profile Image

Senior Investigator

Charles Bradberry, Ph.D.

Preclinical Pharmacology Section


251 Bayview Blvd Suite 200
Baltimore MD 21224
Office: 443-740-2519
Lab: 443-740-2519

charles.bradberry@nih.gov

Charles Bradberry, Ph.D., Chief, Preclinical Pharmacology Section, NIDA.


Post-doctoral training: Neuropsychopharmacology Research Unit, Dept. of Psychiatry, Yale University School of Medicine; Advisor: Dr. Robert H. Roth


Ph.D.: Biochemistry, University of Kansas; Advisor: Dr. Ralph N. Adams


B.S.: Chemistry, University of Kansas



Dr. Bradberry’s section is focused on understanding the neuroscience of drug use and abuse at a systems neuroscience level. To accomplish this, the lab employs multimodal imaging and electrophysiological approaches in combination with sophisticated preclinical behavioral and cognitive models. They study brain mechanisms involved in reward guided choice, because addiction is a behavioral disease marked by disadvantageous choices to use drugs versus beneficial alternative rewards. The section’s previous findings have demonstrated that in well controlled group comparisons, animals that chronically self-administered cocaine showed selective deficits in cognitive functions believed to be mediated by the orbitofrontal cortex, a brain region implicated in reward valuation and selection. These results disentangle the confound that preexisting conditions represent in clinical studies that have also indicated a role for orbitofrontal cortex in addiction. Concurrent longitudinal imaging studies in those same animals are revealing that reductions in brain gray matter levels in the orbitofrontal cortex correlate with the deficits in cognitive performance across individuals, strongly suggesting a causal link. The lab is also working to understand the neural basis of attentional bias to drug-associated environmental cues, which is a strong predictor of relapse among those seeking treatment for addiction. Only the orbitofrontal cortex, among a number of potentially relevant brain regions is selectively activated by the drug cues, further implicating its importance in addiction. Ongoing and future projects will continue to combine the most clinically relevant animal models with state of the art technologies to help discover mechanisms through which drugs and their associated cues control choice behavior, and to use those models for developing novel approaches for treating addiction.

Staff Image
  • 1) Schindler CW, Redhi GH, Vemuri K, Makriyannis A, Le Foll B, Bergman J, Goldberg SR, Justinova Z (2016)
  • Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys
  • Neuropsychopharmacology, 2016 Aug;41(9):2283-93. doi: 10.1038/npp.2016.27.
  • 2) Justinova Z, Panlilio LV, Secci ME, Redhi GH, Schindler CW, Cross AJ, Mrzljak L, Medd A, Shaham Y, Goldberg SR (2015)
  • The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys
  • Biol Psychiatry, 2015 Oct 1;78(7):452-62. doi: 10.1016/j.biopsych.2
  • 3) Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, Mascia P, Bandiera T, Armirotti A, Bertorelli R, Chefer SI, Barnes C, Yasar S, Piomelli D, Goldberg SR (2015)
  • Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse
  • Neuropsychopharmacology, 2015 Aug;40(9):2185-97. doi: 10.1038/npp.2015.62.
  • 4) Narendran R, Jedema HP, Lopresti BJ, Mason NS, Himes ML, Bradberry CW (2015)
  • Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates
  • Biol Psychiatry, 2015 Mar 1;77(5):488-92. doi: 10.1016/j.biopsych.2, Epub 2014 Jun 23
  • 5) Narendran R, Jedema HP, Lopresti BJ, Mason NS, Gurnsey K, Ruszkiewicz J, Chen CM, Deuitch L, Frankle WG, Bradberry CW (2014)
  • Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study
  • Mol Psychiatry, 2014 Mar;19(3):302-10. doi: 10.1038/mp.2013.9. Epu, Erratum in: Mol Psychiatry. 2014 Mar;19(3):399
  • 6) Jedema HP, Narendran R, Bradberry CW. (2014)
  • Amphetamine-induced release of dopamine in primate prefrontal cortex and striatum: striking differences in magnitude and timecourse
  • J Neurochem, 2014 Aug;130(4):490-7. doi: 10.1111/jnc.12743. Epu
  • 7) Justinova Z, Mascia P, Wu HQ, Secci ME, Redhi GH, Panlilio LV, Scherma M, Barnes C, Parashos A, Zara T, Fratta W, Solinas M, Pistis M, Bergman J, Kangas BD, Ferré S, Tanda G, Schwarcz R, Goldberg SR (2013)
  • Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid
  • Nat Neurosci, 2013 Nov;16(11):1652-61. doi: 10.1038/nn.3540. Epu
  • 8) Porter JN, Olsen AS, Gurnsey K, Dugan BP, Jedema HP, Bradberry CW (2011)
  • Chronic cocaine self-administration in rhesus monkeys: impact on associative learning, cognitive control, and working memory
  • J Neurosci, 2011 Mar 30;31(13):4926-34, doi: 10.1523/JNEUROSCI.5426-10.2011
  • 9) Jedema HP, Gianaros PJ, Greer PJ, Kerr DD, Liu S, Higley JD, Suomi SJ, Olsen AS, Porter JN, Lopresti BJ, Hariri AR, Bradberry CW (2010)
  • Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission
  • Mol Psychiatry, 2010 May;15(5):512-22, 446. doi: 10.1038/mp.2009.9
  • 10) Baeg EH, Jackson ME, Jedema HP, Bradberry CW (2009)
  • Orbitofrontal and anterior cingulate cortex neurons selectively process cocaine-associated environmental cues in the rhesus monkey
  • J Neurosci, . 2009 Sep 16;29(37):11619-27, doi: 10.1523/JNEUROSCI.3206-09.2009
View Pubmed Publication